Press Release

Lori Reilly to Lead PhRMA Policy & Research Department

PhRMA May 22, 2013

WASHINGTON, D.C. (May 21, 2013) –  The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Lori Reilly will become Executive Vice President of Policy and Research, effective June 7, 2013. She succeeds Rick Smith, who will retire after 11 years of service with PhRMA. Reilly will report directly to PhRMA President and CEO John Castellani and serve as a member of the PhRMA Management Committee.

Reilly will oversee PhRMA’s policy development and research activities on a broad range of issues, public policies and regulations that affect the biopharmaceutical research sector.

“Lori brings a wealth of experience and great insights on complex policy matters, which have prepared her to effectively lead the high-performing Policy and Research team at PhRMA,” said Castellani. “We all look forward to continuing our work with Lori in addressing major health care challenges, seeking policy solutions that support the development of innovative medicines and ultimately helping patients live longer, healthier lives.”

“I am honored to serve PhRMA as the Executive Vice President for Policy and Research and I look forward to advancing solutions for high-quality, affordable health care in my new capacity,” said Reilly said. “At this important time in health care, I am excited to help lead our work to advance policies to meet patients’ needs through continued biopharmaceutical innovation.”

Reilly has worked at PhRMA for 13 years, serving as Vice President of Policy and Research at PhRMA for the last 8 years. Prior to joining the organization, she was Counsel at the U.S House Committee on Commerce and she also served as Chief of Staff and Counsel to U.S. Representative Jon Christensen (Nebraska). Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln and her J.D. from the University of Nebraska, College of Law.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit